To investigate whether failure to suppress the prostate-specific antigen (PSA) level to or=2 months of neoadjuvant luteinizing hormone-releasing hormone agonist therapy in patients scheduled to undergo external beam radiotherapy for localized prostate carcinoma is associated with reduced biochemical failure-free survival. ⋯ The results of our study have shown that patients with a PSA level >1 ng/mL at the beginning of external beam radiotherapy after >or=2 months of neoadjuvant luteinizing hormone-releasing hormone agonist therapy have a significantly greater rate of biochemical failure and lower survival rate compared with those with a PSA level of
Darren M Mitchell, Jonathan McAleese, Richard M Park, David P Stewart, Stephen Stranex, Ruth L Eakin, Russell F Houston, and Joe M O'Sullivan.
Department of Clinical Oncology, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland. dmmitchell@doctors.org.uk
Int. J. Radiat. Oncol. Biol. Phys. 2007 Dec 1; 69 (5): 1467-71.
PurposeTo investigate whether failure to suppress the prostate-specific antigen (PSA) level to or=2 months of neoadjuvant luteinizing hormone-releasing hormone agonist therapy in patients scheduled to undergo external beam radiotherapy for localized prostate carcinoma is associated with reduced biochemical failure-free survival.Methods And MaterialsA retrospective case note review of consecutive patients with intermediate- or high-risk localized prostate cancer treated between January 2001 and December 2002 with neoadjuvant hormonal deprivation therapy, followed by concurrent hormonal therapy and radiotherapy was performed. Patient data were divided for analysis according to whether the PSA level in Week 1 of radiotherapy was ResultsA total of 119 patients were identified. The PSA level after neoadjuvant hormonal deprivation therapy was 1 ng/mL in 52. At a median follow-up of 49 months, the 4-year actuarial biochemical failure-free survival rate was 84% vs. 60% (p = 0.0016) in favor of the patients with a PSA level after neoadjuvant hormonal deprivation therapy of ConclusionsThe results of our study have shown that patients with a PSA level >1 ng/mL at the beginning of external beam radiotherapy after >or=2 months of neoadjuvant luteinizing hormone-releasing hormone agonist therapy have a significantly greater rate of biochemical failure and lower survival rate compared with those with a PSA level of